Contineum Therapeutics, Inc. Marketable Securities (Current)
Contineum Therapeutics, Inc. (CTNM) had Marketable Securities (Current) of $221.84 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:MarketableSecuritiesCurrent · last filed 2026-07-30
- 2026-06-30: Marketable Securities, Current $221.84M.
- 2026-03-31: Marketable Securities, Current $226.17M.
- 2025-12-31: Marketable Securities, Current $187.29M.
- 2025-09-30: Marketable Securities, Current $139.77M.
| Period end | Marketable Securities, Current |
|---|---|
| 2026-06-30 | $221.84M 10-Q · filed 2026-07-30 |
| 2026-03-31 | $226.17M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $187.29M 10-Q · filed 2026-07-30 |
| 2025-09-30 | $139.77M 10-Q · filed 2025-10-30 |
| 2025-06-30 | $154.70M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $168.24M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $182.82M 10-K · filed 2026-03-05 |
| 2024-09-30 | $173.02M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $141.42M 10-Q · filed 2024-08-14 |
| 2024-03-31 | $101.64M 10-Q · filed 2024-05-16 |
| 2023-12-31 | $109.66M 10-K · filed 2025-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |